Building on this, Liu et al. developed a lentiviral vector co-expressing shmiRs targeting both BCL11A and ZNF410, achieving even higher HbF induction and more effective correction of erythroid phenotypes in preclinical models of sickle cell disease and β-thalassemia [69]. Here, BCL11A is linked to sickle cell disease.